Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.

@article{Nlting2014CombinationO1,
  title={Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.},
  author={Svenja N{\"o}lting and Alessio Giubellino and Yasin Tayem and Karen A. Young and Michael Lauseker and Petra Bullova and Jan Schov{\'a}nek and Miriam Anver and Stephanie Fliedner and M{\'a}rta Korbonits and Burkhard J. G{\"o}ke and George Vlotides and Ashley Grossman and Karel Pacak},
  journal={Endocrinology},
  year={2014},
  volume={155 7},
  pages={2377-90}
}
Currently, there are no reliably effective therapeutic options for metastatic pheochromocytoma (PCC) and paraganglioma. Moreover, there are no therapies that may prevent the onset or progression of tumors in patients with succinate dehydrogenase type B mutations, which are associated with very aggressive tumors. Therefore, we tested the approved and well-tolerated drugs lovastatin and 13-cis-retinoic acid (13cRA) in vitro in an aggressive PCC mouse cell line, mouse tumor tissue-derived (MTT… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Similar Papers

Loading similar papers…